Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an 11% reduction in myocardial infarction (MI)”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“This study showed that each 10 mm Hg decrease in systolic BP (achieved with either an ACE inhibitor [captopril] or a beta blocker [atenolol]) was associated with a 15% reduction in DM-related mortality”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“and a 13% reduction in the microvascular complications of retinopathy or DKD.186”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Clinical trial data show that intensifying therapy with BP-lowering medications slows the progression of DKD and retinopathy, though vigilance in monitoring renal function during intensive BP therapy is recommended.185,186,201–203”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Optimization of glucose and BP are the proven strategies for primary prevention of diabetic retinopathy and for slowing the progression of preexisting nonproliferative retinopathy.78,185,186,193,522,523”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Self-citationReversal of Left Ventricular Hypertrophy in Hypertensive Patients
Dahlöf, B., Pennert, K., & Hansson, L. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.2.95 · Cited by 925
Self-citationLemon, D. (1987) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 563
Research works printed but not linked: 2
- Dhlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705
- Mulrow, 2001, Pharmacotherapy for hypertension in the elderly (Cochrane review)
Cited by
Items 701–800 of 1,018
Neuronal over-expression of ACE2 protects brain from ischemia-induced damage
Chen, J., Zhao, Y., Chen, S., Wang, J., Xiao, X., Ma, X., Penchikala, M., Xia, H., Lazartigues, E., Zhao, B., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.01.004 · Cited by 96
Chen, Y. J., Li, L. J., Tang, W. L., Song, J. Y., Qiu, R., Li, Q., Xue, H., & Wright, J. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008170.pub3 · Cited by 98
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
Aulakh, G. K., Sodhi, R. K., & Singh, M. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.06.007 · Cited by 96
Ruilope, L. M., Malacco, E., Khder, Y., Kandra, A., Bönner, G., & Heintz, D. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.05.006 · Cited by 96
Canoy, D., Copland, E., Nazarzadeh, M., Ramakrishnan, R., Pinho‐Gomes, A., Salam, A., Dwyer, J. P., Farzadfar, F., Sundström, J., Woodward, M., et al. (2022) · Heart · doi:10.1136/heartjnl-2021-320171 · Cited by 95
Is early and fast blood pressure control important in hypertension management?
Volpe, M., Gallo, G., & Tocci, G. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.026 · Cited by 96
Primary Hyperparathyroidism With Concurrent Primary Aldosteronism
Maniero, C., Fassina, A., Guzzardo, V., Lenzini, L., Amadori, G., Pelizzo, M. R., Gomez-Sanchez, C., & Rossi, G. P. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.173948 · Cited by 94
Mancia, G., Facchetti, R., Parati, G., & Zanchetti, A. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835339ac · Cited by 94
Fretheim, A., Odgaard-Jensen, J., Brørs, O., Madsen, S., Njølstad, I., Norheim, O. F., Svilaas, A., Kristiansen, I. S., Thürmer, H., & Flottorp, S. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-33 · Cited by 94
de Zeeuw, D., Akizawa, T., Agarwal, R., Audhya, P., Bakris, G. L., Chin, M., Krauth, M., Lambers Heerspink, H. J., Meyer, C. J., McMurray, J. J., et al. (2013) · American Journal of Nephrology · doi:10.1159/000346948 · Cited by 94
Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection
Ruilope, L. M., Rosei, E. A., Bakris, G. L., Mancia, G., Poulter, N. R., Taddei, S., Unger, T., Volpe, M., Waeber, B., & Zannad, F. M. (2005) · Blood Pressure · doi:10.1080/08037050500230227 · Cited by 95
Genetic Variants of Angiotensin II Receptors and Cardiovascular Risk in Hypertension
Jones, A., Dhamrait, S. S., Payne, J. R., Hawe, E., Li, P., Toor, I. S., Luong, L. A., Wootton, P. T. E., Miller, G. J., Humphries, S. E., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000088853.27673.d0 · Cited by 94
Therapeutic Potential of Renin Inhibitors in the Management of Cardiovascular Disorders
Stanton, A. V. (2003) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200303060-00002 · Cited by 93
Yamamoto, E., Tamamaki, N., Nakamura, T., Kataoka, K., Tokutomi, Y., Dong, Y., Fukuda, M., Matsuba, S., Ogawa, H., & Kim‐Mitsuyama, S. (2008) · Stroke · doi:10.1161/strokeaha.108.517284 · Cited by 93
Plutzky, J., Viberti, G. C., & Haffner, S. M. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00202-7 · Cited by 94
Watanabe, T., Suzuki, J., Yamawaki, H., Sharma, V. K., Sheu, S., & Berk, B. C. (2005) · Circulation · doi:10.1161/circulationaha.104.509760 · Cited by 93
Angiotensin receptor blockers and risk of myocardial infarction: systematic review
McDonald, M. A., Simpson, S. H., Ezekowitz, J. A., Gyenes, G., & Tsuyuki, R. T. (2005) · BMJ · doi:10.1136/bmj.38595.518542.3a · Cited by 92
Coleman, C. I., Baker, W. L., Kluger, J., & White, C. M. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f3ef5e · Cited by 92
Ma, J., Lee, K., & Stafford, R. S. (2006) · Hypertension · doi:10.1161/01.hyp.0000240931.90917.0c · Cited by 92
Drug Treatment of Hypertension: Focus on Vascular Health
Cameron, A. C., Lang, N. N., & Touyz, R. M. (2016) · Drugs · doi:10.1007/s40265-016-0642-8 · Cited by 92
Liu, P., Wang, H., Zhang, F., Chen, Y., Wang, D., & Wang, Y. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.4310 · Cited by 92
III Diretriz sobre tratamento do infarto agudo do miocárdio
Piegas, L. S., Timerman, A., Nicolau, J. C., Mattos, L. A., Neto, J. M. R., Feitosa, G. S., Avezum, Á., Carvalho, A. C. C., Mansur, A. D. P., Timerman, A., et al. (2004) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2004002200001 · Cited by 92
Lim, M. C., Song, Y. J., Seo, S., Yoo, C.-W., Kang, S., & Park, S. (2010) · Onkologie · doi:10.1159/000313823 · Cited by 92
Thunström, E., Manhem, K., Rosengren, A., & Peker, Y. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0998oc · Cited by 91
Role of Beta-blockers in Cardiovascular Disease in 2019
Martínez‐Milla, J., Raposeiras‐Roubín, S., Pascual-Figal, D. A., & Ibáñez, B. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.04.014 · Cited by 91
Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease
Morrell, N. W., Higham, M. A., Phillips, P., Shakur‐Still, H., Robinson, P. J., & Beddoes, R. J. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-88 · Cited by 91
Should Angiotensin II Receptor Blockers and Statins Be Combined?
Nickenig, G. (2004) · Circulation · doi:10.1161/01.cir.0000139857.85424.45 · Cited by 91
Thomopoulos, C., Parati, G., & Zanchetti, A. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001787 · Cited by 91
Cardiovascular Disease and Diabetes
Bloomgarden, Z. T. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.230 · Cited by 91
Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases
Patel, B. M., & Mehta, A. A. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.034 · Cited by 91
β-blockers in hypertension: is carvedilol different?
Messerli, F. H., & Grossman, E. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.01.020 · Cited by 91
Pharmacological Effects of AVE 0991, a Nonpeptide Angiotensin‐(1–7) Receptor Agonist
Santos, R. A. S., & Ferreira, A. J. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00239.x · Cited by 91
The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects
Nagel, J. M., Tietz, A. B., Göke, B., & Parhofer, K. G. (2006) · Metabolism · doi:10.1016/j.metabol.2006.04.011 · Cited by 91
Underuse of ACE Inhibitors and Angiotensin II Receptor Blockers in Elderly Patients With Diabetes
Winkelmayer, W. C., Fischer, M. A., Schneeweiß, S., Wang, P. S., Levin, R., & Avorn, J. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.08.018 · Cited by 91
Pharmacotherapy for mild hypertension
Diao, D., Wright, J. M., Cundiff, D. K., & Gueyffier, F. (2012) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802012000600012 · Cited by 91
Soliman, E. Z., Byington, R. P., Bigger, J. T., Evans, G., Okin, P. M., Goff, D. C., & Chen, H. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06236 · Cited by 90
Okin, P. M., Kjeldsen, S. E., Julius, S., Hille, D. A., Dahlof, B., Edelman, J. M., & Devereux, R. B. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq225 · Cited by 90
Self-citation2010 Guidelines of the Taiwan Society of Cardiology for the Management of Hypertension
Chiang, C., Wang, T., Li, Y.-H., Lin, T., Chien, K., Yeh, H., Shyu, K., Tsai, W.-C., Chao, T.-H., Hwang, J., et al. (2010) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(10)60120-9 · Cited by 90
Cardiovascular disease in chronic kidney disease from a cardiologistʼs perspective
McCullough, P. A. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200411000-00003 · Cited by 90
Benčić, M. L., Sikirić, P., Hanževački, J. Š., Seiwerth, S., Rogić, D., Kuŝec, V., Aralica, G., Konjevoda, P., Batelja, L., & Blagaić, A. B. (2004) · Journal of Pharmacological Sciences · doi:10.1254/jphs.95.19 · Cited by 90
Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy
de Zeeuw, D. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.002 · Cited by 89
Pepine, C. J., Handberg, E. M., & COOPERDEHOFF, R. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.12.023 · Cited by 89
Savoia, C., Touyz, R. M., Endemann, D. H., Pu, Q., Ko, E. A., De Ciuceis, C., & Schiffrin, E. L. (2006) · Hypertension · doi:10.1161/01.hyp.0000230234.84356.36 · Cited by 89
Niklason, A., Hedner, T., Niskanen, L., & Lanke, J. (2004) · Journal of Hypertension · doi:10.1097/00004872-200403000-00029 · Cited by 89
Brown, M. J. (2007) · Heart · doi:10.1136/hrt.2006.107706 · Cited by 89
The role of angiotensin II in nonalcoholic steatohepatitis
Morris, E. M., Fletcher, J. A., Thyfault, J. P., & Rector, R. S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.04.013 · Cited by 88
The Prevention of Type 2 Diabetes Mellitus
Inzucchi, S. E., & Sherwin, R. S. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.11.008 · Cited by 88
Treatment of hypertension in peripheral arterial disease
Lane, D. A., & Lip, G. Y. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003075.pub3 · Cited by 88
Irbesartan: A Review of its Use in Hypertension and in the Management of Diabetic Nephropathy
Croom, K. F., Curran, M. P., Goa, K. L., & Perry, C. M. (2004) · Drugs · doi:10.2165/00003495-200464090-00011 · Cited by 88
Kushiro, T., Itakura, H., Abo, Y., Gotou, H., Terao, S., & Keefe, D. L. (2006) · Hypertension Research · doi:10.1291/hypres.29.997 · Cited by 88
Sacco, S., Pistoia, F., Degan, D., & Carolei, A. (2014) · Cephalalgia · doi:10.1177/0333102414559551 · Cited by 88
Small artery remodelling in hypertension: causes, consequences and therapeutic implications
Mulvany, M. J. (2008) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-008-0305-3 · Cited by 88
Drenger, B., Fontes, M. L., Miao, Y., Mathew, J. P., Gozal, Y., Aronson, S., Dietzel, C., & Mangano, D. T. (2012) · Circulation · doi:10.1161/circulationaha.111.059527 · Cited by 88
Nomura, S., Shouzu, A., Omoto, S., Nishikawa, M., & Iwasaka, T. (2004) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602960401000203 · Cited by 87
McMurray, J. J. V. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr093 · Cited by 87
Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay
Niswender, K. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01175.x · Cited by 87
Ramipril treatment suppresses islet fibrosis in Otsuka Long–Evans Tokushima fatty rats
Ko, S.-H., Kwon, H.-S., Kim, S.-R., Moon, S.-D., Ahn, Y.-B., Song, K.-H., Son, H.-S., Cha, B.-Y., Lee, K.-W., Son, H.-Y., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.023 · Cited by 87
Trenkwalder, P., Elmfeldt, D., Hofman, A., Lithell, H., Olofsson, B., Papademetriou, V., Skoog, I., & Zanchetti, A. (2005) · Blood Pressure · doi:10.1080/08037050510008823 · Cited by 87
East, M. A., Jollis, J. G., Nelson, C. L., Marks, D., & Peterson, E. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)03006-1 · Cited by 88
Protective Role of Antioxidants in Diabetes-Induced Cardiac Dysfunction
Vassort, G., & Turan, B. (2010) · Cardiovascular Toxicology · doi:10.1007/s12012-010-9064-0 · Cited by 87
Authors Task Force Members, Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., et al. (2007) · European Heart Journal Supplements · doi:10.1093/eurheartj/ehl261 · Cited by 87
Yang, J., Jiang, H., Yang, J., Ding, J.-W., Chen, L., Song, L., & Zhang, X. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0098-1 · Cited by 87
Protective arms of the renin–angiotensin‐system in neurological disease
Sumners, C., Horiuchi, M., Widdop, R. E., McCarthy, C. A., Unger, T., & Steckelings, U. M. (2013) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12137 · Cited by 87
Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy? Time for Another Look
Reudelhuber, T. L., Bernstein, K. E., & Delafontaine, P. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.075085 · Cited by 87
Okin, P. M., Devereux, R. B., Gerdts, E., Snapinn, S. M., Harris, K. E., Jern, S., Kjeldsen, S. E., Julius, S., Edelman, J. M., Lindholm, L. H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.574822 · Cited by 87
Self-citationRAAS Inhibitors and Cardiovascular Protection in Large Scale Trials
von Lueder, T. G., & Krum, H. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6424-y · Cited by 87
Wessels, A. M., Siemers, E. R., Yu, P., Andersen, S. W., Holdridge, K. C., Sims, J. R., Sundell, K., Stern, Y., Rentz, D. M., Dubois, B., et al. (2015) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2015.82 · Cited by 86
Prevention of Stroke in Patients with Hypertension
Dahlöf, B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.010 · Cited by 86
Self-citationNew Treatment Strategies for Patients with Hypertension and Insulin Resistance
Kurtz, T. W. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.011 · Cited by 86
Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus
DePaula, A. L., Macedo, A. L. V., Rassi, N., Vencio, S. A. C., Machado, C. A., Mota, B., Silva, L. Q., Halpern, A., & Schraibman, V. (2008) · Surgical Endoscopy · doi:10.1007/s00464-008-9808-0 · Cited by 86
Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials
Thomopoulos, C., Bazoukis, G., Tsioufis, C., & Mancia, G. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002523 · Cited by 86
Verdecchia, P., Angeli, F., Cavallini, C., Gattobigio, R., Gentile, G., Staessen, J. A., & Reboldi, G. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn575 · Cited by 86
Chrysant, S. G., Marbury, T. C., & Robinson, T. D. (2003) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001577 · Cited by 86
South African hypertension guideline 2011.
Seedat, Y. K., & Rayner, B. L. (2011) · PubMed · doi:10.7196/samj.1111 · Cited by 86
Mancia, G., Kjeldsen, S. E., Kreutz, R., Pathak, A., Grassi, G., & Esler, M. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19020 · Cited by 85
Self-citationLee, M. H., Song, H. K., Ko, G. J., Kang, Y. S., Han, S. Y., Han, K. H., Kim, H. K., Han, J., & Cha, D. R. (2008) · Kidney International · doi:10.1038/ki.2008.313 · Cited by 85
Krikov, M., Thone-Reineke, C., Müller, S., Villringer, A., & Unger, T. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f2dac9 · Cited by 85
Crowley, S. D., Song, Y.-S., Sprung, G., Griffiths, R., Sparks, M., Yan, M., Burchette, J. L., Howell, D. N., Lin, E. E., Okeiyi, B., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.144964 · Cited by 85
Use of composite endpoints in clinical trials
Sankoh, A. J., Li, H., & D’Agostino, R. B. (2014) · Statistics in Medicine · doi:10.1002/sim.6205 · Cited by 85
Cuspidi, C., Rescaldani, M., Sala, C., Negri, F., Grassi, G. M., & Mancia, G. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835726a3 · Cited by 85
Recomendaciones preventivas cardiovasculares
Galán, Á. M. M., Cuixart, C. B., Álvarez, F. V., Pérez, J. N., Lobos-Bejarano, J. M., Sánchez-Pinilla, R. O., Rioboó, E. M., Banegas, J. R. B., Orozco‐Beltrán, D., & Gil-Guillén, V. F. (2012) · Atención Primaria · doi:10.1016/s0212-6567(12)70010-0 · Cited by 87
Cooper‐DeHoff, R. M., Cohen, J. D., Bakris, G. L., Messerli, F. H., Erdine, S. E., Hewkin, A. C., Kupfer, S., & Pepine, C. J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.04.030 · Cited by 85
Perazella, M. A., & Setaro, J. F. (2003) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2003.392 · Cited by 84
Hypertensive myocardial fibrosis
Cuspidi, C., Ciulla, M., & Zanchetti, A. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi237 · Cited by 84
Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials
Verdecchia, P., Gentile, G., Angeli, F., Mazzotta, G., Mancia, G., & Reboldi, G. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328338e2bb · Cited by 84
Systolic Hypertension in the Elderly: Addressing an Unmet Need
Duprez, D. A. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.10.027 · Cited by 84
Renin–Angiotensin System Blocking Drugs
Robles, N. R., Cerezo, I., & Hernández‐Gallego, R. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413501018 · Cited by 84
Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control
Sarafidis, P. A., & Bakris, G. L. (2006) · QJM · doi:10.1093/qjmed/hcl059 · Cited by 84
SIIA Task Force, Borghi, C., SIF Task Force, & Rossi, F. (2015) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-015-0120-5 · Cited by 83
Atherosclerosis and Vascular Calcification in Chronic Renal Failure
Campean, V., Neureiter, D., Varga, I., Runk, F., Reiman, A., Garlichs, C., Achenbach, S., Nonnast-Daniel, B., & Amann, K. (2005) · Kidney and Blood Pressure Research · doi:10.1159/000090182 · Cited by 83
Fujimura, N., Noma, K., Hata, T., Soga, J., Hidaka, T., Idei, N., Fujii, Y., Mikami, S., Maruhashi, T., Iwamoto, Y., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.227 · Cited by 83
Effects of Candesartan on Cardiovascular Outcomes in Japanese Hypertensive Patients
SUZUKI, H., & KANNO, Y. (2005) · Hypertension Research · doi:10.1291/hypres.28.307 · Cited by 83
Chang, C., Lin, J., Wu, L., & Lai, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.1908 · Cited by 83
The renin–angiotensin system contributes to renal fibrosis through regulation of fibrocytes
Sakai, N., Wada, T., Matsushima, K., Bucala, R., Iwai, M., Horiuchi, M., & Kaneko, S. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f3e9e6 · Cited by 83
Risk Factor Management to Prevent First Stroke
Rundek, T., & Sacco, R. L. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.09.001 · Cited by 84
Prevention and management of stroke in very elderly patients
Sanossian, N., & Ovbiagele, B. I. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70259-5 · Cited by 85
A Review of ACE Inhibitors and ARBs in Black Patients With Hypertension
Helmer, A. M., Slater, N. A., & Smithgall, S. E. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018779082 · Cited by 83
Hipertensão arterial sistêmica primária
Nobre, F. D., Coelho, E. B., Lopes, P. C., & Geleilete, T. J. M. (2013) · Medicina (Ribeirão Preto) · doi:10.11606/issn.2176-7262.v46i3p256-272 · Cited by 83
Cardiac transcriptional response to acute and chronic angiotensin II treatments
Larkin, J. E., Frank, B. C., Gaspard, R. M., Duka, I., Gavras, H., & Quackenbush, J. (2004) · Physiological Genomics · doi:10.1152/physiolgenomics.00057.2004 · Cited by 82
Review: Potential of renin inhibition in cardiovascular disease
Stanton, A. V. (2003) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2003.008 · Cited by 82
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Michigan (US)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Corresponding author
- Dahlöf, Björn
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 995-1003
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133217116
- Cited by
- 5,407
- References
- 29
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 69 · 2022: 63 · 2021: 75 · 2020: 74 · 2019: 82 · 2018: 106 · 2017: 144 · 2016: 131 · 2015: 152 · 2014: 208 · 2013: 200 · 2012: 265
- FWCI
- 333.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- atenolol, essential hypertension, left ventricular hypertrophy, angiotensin receptor blockers, beta-blockers, cardiovascular morbidity, cardiovascular mortality, stroke, myocardial infarction, blood pressure reduction, new-onset diabetes, antihypertensive therapy, elderly patients, secondary prevention of cardiovascular disease, renin-angiotensin system blockade
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.